Crossmark

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Crossref DOI link: https://doi.org/10.1186/s40425-019-0693-y

Published Online: 2019-08-26

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Jinyu

Larrocha, Pablo Saenz-lopez

Zhang, Bin

Wainwright, Derek

Dhar, Payal

Wu, Jennifer D. http://orcid.org/0000-0002-8925-268X
Funding

Funding for this research was provided by:

National Cancer Institute (R01CA208246, R01CA204021)

National Institutes of Health (T32 CA080621)
License Information

Text and Data Mining valid from 2019-08-26
More Information

Article History

Received: 22 March 2019

Accepted: 24 July 2019

First Online: 26 August 2019

Ethics approval and consent to participate

: All animal studies were approved by the Institutional Animal Care and Use Committee at the Medical University of South Carolina and Northwestern University.

: Not applicable.

: Jennifer D. Wu is the inventor of the anti-sMIC antibody B10G5 which holds international patent for the composition of matter. All other authors declare no conflict of interest.

Document is current

Any future updates will be listed below